Tumor budding in gastric adenocarcinoma; reflections on tumor microenvironment and programmed death ligand 1 (PD-L1) expression

نویسندگان

چکیده

Introduction: The significance of tumor budding and programmed death ligand 1 (PD-L1) has not been established in gastric adenocarcinoma (GAC). Objectives: This study evaluated PD-L1 expression with regard to microenvironment, clinicopathologic parameters, overall survival GAC. Patients Methods: Totally, 102 GAC cases were assessed immunohistochemically. associations features, tumor-infiltrating lymphocytes (TILs), stroma percentage (TSP), analyzed. Results: High (42.2% cases) was correlated distal location, large size, Helicobacter pylori infection, poor differentiation (P = 0.0008, 0.033, 0.011, 0.005, respectively), lymphovascular invasion, high nodal stages, TSP (all P < 0.0001). Tumor highest the low TILs/high group. (43.1% proximal location (p 0.00021), 0.036), N stage 0.049), TILs 0.0001), 0.002). / category Cox regression showed that (hazard ratio [HR]: 15.282, 0.024, 95% confidence interval [CI]: 1.441–162.069) positive (HR: 7.502, 0.015, CI: 1.469–38.31) independent prognostic factors for survival. Conclusion: is whereas inversely budding. Both are predictors short Anti-PD-L1 immunotherapy could be effective metastasis, especially

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Programmed death ligand 1 (PD-L1) expression and tumor infiltrating lymphocytes in glioblastoma Running title: PD-L1 expression in glioblastoma

BACKGROUND Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L1) showed activity in several cancer types. METHODS We performed immunohistochemistry for CD3, CD8, CD20, HLA-DR, phosphatase and tensin homolog (PTEN), PD-1, and PD-L1 and pyrosequencing for assessment of the O6-methylguanine-methyltransferase (MGMT) promoter methylation status in 135 glioblastom...

متن کامل

Programmed death-ligand 1 (PD-L1) expression in various tumor types

Background Programmed cell death-1 (PD-1) is a co-inhibitory receptor expressed on lymphoid and non-lymphoidderived cells that negatively regulates peripheral T-cell responses. PD-L1, the major PD-1 ligand, is expressed on various tumors and is being investigated as a possible predictive marker for anti-PD-1 therapy. Few studies have determined PD-L1 expression across tumor types using a consis...

متن کامل

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma

Angiosarcomas are rare malignant endothelial-cell tumors of vascular or lymphatic origin, and are among the most aggressive subtypes of soft-tissue sarcomas. The prognosis is poor and treatment is challenging in many cases. PD-1/PD-L1 pathway plays a critical role in immune escape of tumor cells. Recent studies described that PD-L1 is widely expressed in various types of cancer, providing the b...

متن کامل

Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma

Chordomas are primary malignant tumors of the notochord that are resistant to conventional chemotherapy. Expression of programmed cell death ligand 1 (PD-L1), prevalence of tumor-infiltrating lymphocytes (TILs), and their clinical relevance in chordoma remain unknown. We evaluated PD-L1 expression in three chordoma cell lines and nine chordoma tissue samples by western blot. Immunohistochemical...

متن کامل

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy

The identification of biomarkers associated with response to therapeutic agents is central to optimizing patient outcomes. Expression of the immune checkpoint proteins PD-1/L1, and DNA mismatch repair deficiency (dMMR) status may be predictive response biomarkers for immunotherapies, but their overlap requires further study. We prospectively conducted PD-L1 and MMR immunohistochemistry (IHC) on...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Immunopathologia Persa

سال: 2022

ISSN: ['2423-8015']

DOI: https://doi.org/10.34172/ipp.2022.31365